Introduction {#s001}
============

Systemic chemotherapy remains the standard of care for patients with metastatic pancreatic cancer (MPC) despite the introduction of novel approaches, such as targeted therapy and immune checkpoint inhibitors, in other malignancies.^[@B1],[@B2]^ In 1997, gemcitabine monotherapy was established as the standard of care in MPC, with subsequent trials using combination therapies with a gemcitabine-based backbone failing to demonstrate a clinically and statistically significant improvement in survival.^[@B3]^ In 2011, the PRODIGE 4/ACCORD 11 trial reported the FOLFIRINOX regimen (leucovorin, 5-fluorouracil \[5-FU\], irinotecan, and oxaliplatin), and, in 2013, the MPACT trial reported the combination of *nab*-paclitaxel plus gemcitabine. Each regimen demonstrated significantly longer overall survival (OS) than gemcitabine monotherapy in their respective phase III trials.^[@B9]^ In PRODIGE 4/ACCORD 11, the median OS was 11.1 months with FOLFIRINOX versus 6.8 months with gemcitabine monotherapy (HR, 0.57 \[95% confidence interval (CI), 0.45--0.73\]; *p* \< 0.001).^[@B9]^ The MPACT trial demonstrated a median OS of 8.7 months with *nab*-paclitaxel plus gemcitabine versus 6.6 months with gemcitabine monotherapy (HR, 0.72 \[95% CI, 0.62--0.83\]; *p* \< 0.001).^[@B11]^ On the basis of these results, either *nab*-paclitaxel plus gemcitabine or FOLFIRINOX are considered preferred regimens for the first-line treatment of patients with MPC.^[@B2]^

Although both regimens demonstrated a survival benefit, the patient\'s age, performance status and nutritional intake, and the regimen\'s distinct safety profiles are important considerations when selecting treatments for patients and designing prospective clinical trials. In the PRODIGE 4/ACCORD 11 trial, common grade 3/4 hematological adverse events associated with FOLFIRINOX were neutropenia (45.7%), thrombocytopenia (9.1%), anemia (7.8%), and febrile neutropenia (5.4%); common nonhematological adverse events were fatigue (23.6%), vomiting (14.5%), diarrhea (12.7%), sensory neuropathy (9.0%), elevated levels of alanine aminotransferase (7.3%), and thromboembolism (6.6%).^[@B9]^ In the MPACT trial, common grade ≥3 hematological adverse events associated with *nab*-paclitaxel plus gemcitabine were neutropenia (38%), leukopenia (31%), thrombocytopenia (13%), and anemia (13%); common nonhematological adverse events were fatigue (17%), peripheral neuropathy (17%), and diarrhea (6%).^[@B10],[@B11]^

In an effort to mitigate safety concerns with high-dose intermittent chemotherapy while retaining efficacy of combination regimens, multiple strategies have been used, including metronomic dosing and alternating or in-tandem administration of *nab*-paclitaxel and FOLFIRINOX. Isacoff et al. evaluated low-dose metronomic chemotherapy with 5-FU, *nab*-paclitaxel, leucovorin, and oxaliplatin plus bevacizumab in 65 patients with advanced PC and reported the results in a retrospective analysis.^[@B12]^ Unfortunately, toxicity was still a concern with this regimen, and 22 patients discontinued treatment due to adverse events; however, efficacy was encouraging, with a median OS of 19 months and an objective response rate of 49%. Similarly, retrospective reports of other metronomic regimens, such as POLF (paclitaxel, oxaliplatin, leucovorin, and 5-FU) and PILF (paclitaxel, irinotecan, leucovorin, and 5-FU) support the continued investigation of low-dose metronomic regimens for the treatment of MPC.^[@B13]^

Additional combination therapies have been evaluated in single-arm studies of FOLFOX-A (leucovorin, 5-FU, oxaliplatin, and *nab*-paclitaxel)^[@B14]^ as well as the alternation or in-tandem administration of *nab*-paclitaxel and FOLFIRINOX in the GABRINOX, SEENA-1, and NabucCO studies, which all reported safety profiles comparable with those demonstrated in the MPACT and PRODIGE trials.^[@B15]^ These studies demonstrate that toxicity remains a concern with combination chemotherapy regimens despite promising efficacy.

In this study we report the phase I results of a multicenter single-arm study investigating the regimen of metronomic 5-FU plus *nab*-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with newly diagnosed MPC. The oxaliplatin and *nab*-paclitaxel doses were lower than those administered in the study by Isacoff et al. in an effort to reduce toxicity while maintaining efficacy.^[@B18]^ Previous preclinical and clinical investigations have suggested that bevacizumab and other similar antiangiogenic therapies may prolong the antitumor effect of paclitaxel.^[@B19],[@B20]^ The primary objective of this study was to determine dose-limiting toxicities (DLTs) of metronomic FABLOx in patients with newly diagnosed MPC.

Methods {#s002}
=======

The study was approved by each participating site\'s institutional review board or independent ethics committee and was conducted in compliance with the International Council for Harmonisation Good Clinical Practice guidelines and with the general ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all patients before study entry. This study was registered on [ClinicalTrials.gov](ClinicalTrials.gov) under NCT02620800.

Patients {#s003}
--------

Owing to limited experience and the toxicities associated with this five-drug regimen, patient enrollment was limited to those with good performance status, limited comorbidities, and age ≤65 years. Patients (aged 18--65 years) with histologically or cytologically confirmed MPC, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1 or 0, and no prior systemic chemotherapy or investigational therapy (other than as a radiosensitizer) for PC were eligible. Adequate blood and organ function as well as measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 were required for inclusion.^[@B21]^ Patients were excluded if they had grade \>1 peripheral neuropathy, a history of malignancy other than PC in the past 3 years, known brain metastases, or an allergy/hypersensitivity to any investigational products or any of their excipients.

Study design {#s004}
------------

In this multicenter single-arm phase I dose de-escalation study, the regimen was given as follows: 5-FU 180 mg/m^2^ per day on days 1 to 14 through continuous infusion; *nab*-paclitaxel 75 mg/m^2^ intravenously (IV) on days 1, 8, and 15; bevacizumab 5 mg/kg IV on days 1 and 15; leucovorin 20 mg/m^2^ IV on days 1, 8, and 15; and oxaliplatin 40 mg/m^2^ IV on days 1, 8, and 15 in each 28-day treatment cycle (the order of receipt of agents is summarized in [Fig. 1](#f1){ref-type="fig"}; the planned dose de-escalation protocol is summarized in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). As noted previously, the oxaliplatin and *nab*-paclitaxel doses were lower than those administered in the study by Isacoff et al. in an effort to potentially reduce toxicity.^[@B18]^ Patients were treated until disease progression, unacceptable toxicity, withdrawal of consent, physician decision, or death.

![Study design for phase I. ^a^Initially, 6 patients were enrolled at dose level 1, but the cohort was expanded to 12 patients based on investigators\' recommendation. 5-FU, 5-fluorouracil; CI, continuous infusion; DLT, dose-limiting toxicity; *nab*-P, *nab*-paclitaxel.](fig-1){#f1}

Assessment of safety end-points and preliminary efficacy {#s005}
--------------------------------------------------------

The primary end-point was the incidence of DLTs, assessed in cycle 1 (DLTs are defined in [Supplementary Table S2](#SD1){ref-type="supplementary-material"}). A minimum of six patients were to be enrolled in each consecutive dosing cohort. If DLTs occurred in more than or equal to two of six patients, the dose would be de-escalated. Safety was continuously evaluated by incidence and severity of treatment-emergent adverse events (TEAEs) according to the Medical Dictionary for Regulatory Activities and the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.

Progression-free survival (PFS) and OS were represented by Kaplan--Meier curves and median survival times with respective 95% CIs. After treatment discontinuation, each patient was followed up for disease progression and survival every 90 days for a minimum of 18 months. The objective response rate was assessed by computed tomography or magnetic resonance imaging according to RECIST v1.1 criteria; results are presented by frequency and percentages with 95% CIs reported for the proportion of responsive patients (complete or partial response) from the total number of patients evaluable for response by RECIST criteria.

Statistical methods {#s006}
-------------------

A minimum of six patients could be enrolled in each consecutive dosing cohort, with enrollment of additional patients per the investigators\' recommendation based on the totality of the data, to further evaluate any dose level. A total of 12--24 patients were planned for enrollment, depending on the number of dose levels examined and number of patients enrolled at each dose level.

Results {#s007}
=======

Patient disposition {#s008}
-------------------

A total of 19 patients were screened for inclusion, but 7 were excluded at screening (MPC not confirmed, unacceptable blood chemistry levels at screening, did not agree to participate in the study, pregnant/nursing \[lactating\] woman, or other significant medical condition, laboratory abnormality, or psychiatric illness that prevented participation in the study). The treated and response-evaluable populations consisted of 12 patients. All patients discontinued treatment, with the majority discontinuing due to progressive disease (*n* = 7) followed by adverse events (*n* = 4) and withdrawal by patient (*n* = 1).

Baseline characteristics {#s009}
------------------------

Patient demographics and baseline characteristics are described in [Table 1](#T1){ref-type="table"}. The median age was 57.5 years and most patients (75.0%) were male. The most common sites of metastasis were the liver (83.3%), peritoneum (66.7%), and lung/thoracic cavity (41.7%).

###### 

Baseline Demographics and Characteristics

  Characteristic                                                   *N* = 12
  ---------------------------------------------------------------- ---------------
  Age, median (range), years                                       57.5 (41--64)
  Gender, *n* (%)                                                  
   Male                                                            9 (75.0)
   Female                                                          3 (25.0)
  Eastern Cooperative Oncology Group performance status, *n* (%)   
   0                                                               7 (58.3)
   1                                                               5 (41.7)
  Site(s) of metastasis, *n* (%)                                   
   Liver                                                           10 (83.3)
   Peritoneum                                                      8 (66.7)
   Lungs/mediastinum                                               5 (41.7)
   Other                                                           2 (16.7)
  No. of metastatic sites                                          
   1                                                               4 (33.3)
   2                                                               3 (25.0)
   3                                                               5 (41.7)
   \>3                                                             0

Safety {#s010}
------

Six patients were enrolled in the first dose cohort. One patient experienced two DLTs (grade 3 anemia requiring a transfusion and grade 3 mucositis unresponsive to medical treatment within 4 days of onset). The starting dose cohort was expanded from 6 to 12 patients to further evaluate the rates of mucositis, per the investigators\' recommendation. No additional DLTs were observed in the expanded cohort. Dose de-escalation was not required.

A summary of TEAEs is provided in [Table 2](#T2){ref-type="table"}. The most common TEAEs of grade ≥3 were abdominal pain, fatigue, mucositis, and decreased neutrophil count. Sepsis was the only grade 4 TEAE (one patient, not suspected to be related to any study drug). One patient experienced a grade 3 serious adverse event of peritoneal infection that worsened to a grade 5 event. Seven patients experienced ≥1 serious TEAE.

###### 

Safety

                                            *N* = 12
  ----------------------------------------- ------------
  Patients with ≥1 grade ≥3 TEAE, *n* (%)   12 (100.0)
  Patients with ≥1 serious TEAE, *n* (%)    7 (58.3)

  AE, *n* (%)                             Grade 1/2^[a](#tf1){ref-type="table-fn"}^   Grade ≥3 (occurring in ≥10% of patients)
  --------------------------------------- ------------------------------------------- ------------------------------------------
  Hematological AEs                                                                   
   Neutrophil count decreased             0                                           3 (25.0)
   Anemia                                 1 (8.3)                                     2 (16.7)
  Nonhematological AEs                                                                
   Abdominal pain                         5 (41.7)                                    3 (25.0)
   Fatigue                                8 (66.7)                                    3 (25.0)
   Mucosal inflammation                   3 (25.0)                                    3 (25.0)
   Alanine aminotransferase increased     0                                           2 (16.7)
   Blood alkaline phosphatase increased   1 (8.3)                                     2 (16.7)
   Nausea                                 5 (41.7)                                    2 (16.7)
   Peripheral sensory neuropathy          3 (25.0)                                    2 (16.7)
   Stomatitis                             4 (33.3)                                    2 (16.7)

Inclusion of grade 1/2 AEs are based on inclusion criteria for grade ≥3 AEs.

AE, adverse event; TEAE, treatment-emergent adverse event.

Treatment exposure and dose modifications {#s011}
-----------------------------------------

All patients were treated at the starting dose level. Treatment exposure and dose modifications for each agent within the FABLOx regimen are summarized in [Table 3](#T3){ref-type="table"}. The median treatment duration was 27--28 weeks for all agents in the FABLOx regimen except oxaliplatin, for which the median treatment duration was 22 weeks.

###### 

Treatment Exposure and Dose Modifications

                                               *N* = 12                                                                                            
  -------------------------------------------- ------------------------- ------------------------- ---------------------- ------------------------ ------------------------------
  Treatment exposure                                                                                                                               
   Treatment duration, median (range), weeks   27.85 (3.7--51.4)         27.00 (3.7--51.4)         27.85 (3.7--51.4)      22.00 (3.7--51.4)        28.00 (3.9--53.6)
   Treatment cycles, median (range), *n*       7.0 (1--13)               7.0 (1--13)               7.0 (1--13)            5.5 (1--13)              7.0 (1--13)
   Relative dose intensity, median, %          94.02                     88.25                     93.64                  88.41                    84.35
   Cumulative dose, median (range), mg         4685.50 (500.0--8217.0)   1343.63 (222.0--2737.9)   413.87 (57.9--728.9)   573.73 (115.8--1462.2)   14,253.36 (2161.6--25,630.9)
  Dose modifications                                                                                                                               
   Patients with ≥1 dose reduction, *n* (%)    0                         5 (41.7)                  0                      6 (50.0)                 7 (58.3)
   Patients with ≥1 dose delay, *n* (%)        5 (41.7)                  5 (41.7)                  5 (41.7)               5 (41.7)                 5 (41.7)

Efficacy {#s012}
--------

The objective response rate (best response: complete, or partial response) was 33% and the disease control rate (complete response, partial response, or stable disease) was 92%; four patients achieved a partial response and seven had stable disease ([Table 4](#T4){ref-type="table"}). The median PFS was 5.6 months (95% CI, 1.7--11.3) and the 1-year PFS rate was 12.2% (95% CI, 0.7--40.8; [Fig. 2](#f2){ref-type="fig"}). The median OS was 9.9 months (95% CI, 4.4--13.2) and the 1-year estimated OS rate was 38.9% (95% CI, 12.6--65.0%; [Fig. 3](#f3){ref-type="fig"}).

![Progression-free survival.](fig-2){#f2}

![Overall survival.](fig-3){#f3}

###### 

Response Rates

  Outcome, *n* (%)                                       *N* = 12
  ------------------------------------------------------ ------------
  Best overall response                                  
   Complete response                                     0
   Partial response                                      4 (33.3)
   Stable disease^[a](#tf3){ref-type="table-fn"}^        7 (58.3)
   Progressive disease                                   1 (8.3)
  Objective response rate                                4 (33.3)
   95% confidence interval                               13.8--60.9
  Disease control rate^[a](#tf3){ref-type="table-fn"}^   11 (91.7)

Minimum time to stable disease was not specified in the protocol.

Discussion {#s013}
==========

This phase I trial evaluated the safety of the FABLOx regimen in patients with MPC. Results from this study suggest that the FABLOx regimen is both feasible and tolerable in patients with MPC with an ECOG PS of 0 or 1, good organ function, and no prior systemic chemotherapy. The FABLOx regimen evaluated in this study demonstrated similar tolerability to the combination therapy regimen reported by Isacoff et al.^[@B12]^ In the Isacoff et al. study, 22 patients (34%) discontinued due to toxicity, which is similar to this study, in which four patients (33%) treated with FABLOx discontinued due to adverse events.^[@B12]^

Multidrug cytotoxic regimens have shown improvement in survival in patients with MPC compared with gemcitabine monotherapy but at the expense of increased toxicity.^[@B9],[@B10]^ Multiple trials are evaluating alternative cytotoxic regimens in an attempt to further improve efficacy without increasing toxicity. In the single-arm study by Safran et al. at a single institution, the FOLFOX-A regimen resulted in a median survival of 15 months in patients with MPC and had a comparable toxicity profile to that of standard-of-care regimens.^[@B14]^ Similarly, in an attempt to reduce toxicity and the early development of chemotherapy resistance, a few trials have studied alternating gemcitabine- and 5-FU-based regimens. The phase I/II GABRINOX study investigated sequential monthly administration of *nab*-paclitaxel plus gemcitabine followed by FOLFIRINOX in patients with MPC. The median OS was reported to be 17.8 months, which was encouraging; however, the rates of grade 3/4 thrombocytopenia, neutropenia, and diarrhea were higher than expected.^[@B9],[@B10],[@B15]^ In the phase II SEENA-1 study, either *nab*-paclitaxel plus gemcitabine was followed by modified FOLFIRINOX (no bolus 5-FU), or *nab*-paclitaxel plus gemcitabine was given alternating with modified FOLFIRI (5-FU, leucovorin, and irinotecan) for up to 48 weeks.^[@B17],[@B22]^ The efficacy results were modest (median OS, 12.3 months in all patients and 13.5 months in patients with disease control after 8 weeks of *nab*-paclitaxel plus gemcitabine), and the safety profile was generally similar to that in the MPACT and PRODIGE 4/ACCORD 11 trials, with common grade ≥3 toxicities, including neutropenia (43%), fatigue (22%), anemia (21%), and thrombocytopenia (15%).^[@B9],[@B10],[@B17]^ A single-institution extension of the SEENA-1 regimen of alternating *nab*-paclitaxel plus gemcitabine with FOLFIRI reported improved survival outcomes (median OS, 16.3 months).^[@B22]^ Recently, the phase II NabucCO study investigated the effect of modifying FOLFIRINOX by replacing either oxaliplatin (*nab*-FOLFIRI) or irinotecan (*nab*-FOLFOX) with *nab*-paclitaxel.^[@B16]^ These modified regimens demonstrated similar survival to that with FOLFIRINOX (median OS, 10.8--13.2 months) but with lower rates of neutropenia.

Overall, these studies examining *nab*-paclitaxel- and 5-FU-based regimens have demonstrated feasibility and relatively consistent survival outcomes; however, they are limited by their design (single-arm and single-institution studies). The survival results with FABLOx are similar to those with other prospectively evaluated combination regimens that have reported median OS values ranging from 7.3 to 13.2 months.^[@B16],[@B23],[@B24]^ The adverse event profile of FABLOx is also consistent with that reported in previous studies.^[@B16],[@B17],[@B25]^ This study supports the relatively consistent outcomes observed with the use of *nab*-paclitaxel- and 5-FU-based regimens in MPC treatment. Although treatment with FABLOx is feasible in patients with MPC, further investigation is not planned due to the lack of significant improvement in efficacy and the need for exigent 2-week continuous 5-FU infusion. These results further underscore the need for novel agents and greater insight into the biology of PC to understand how to better treat this patient population.

Conclusion {#s014}
==========

Results from phase I of this study demonstrate a tolerable safety profile for metronomic FABLOx in patients with newly diagnosed MPC, but preliminary efficacy data are inconclusive for continued investigation in a phase II trial, given the small number of patients in the study.
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5-FU

:   5-fluorouracil

DLTs

:   dose-limiting toxicities

ECOG PS

:   Eastern Cooperative Oncology Group performance status

FABLOx

:   metronomic 5-fluorouracil plus *nab*-paclitaxel, bevacizumab, leucovorin, and oxaliplatin

IV

:   intravenously

MPC

:   metastatic pancreatic cancer

OS

:   overall survival

PFS

:   progression-free survival

PILF

:   paclitaxel, irinotecan, leucovorin, and 5-FU

POLF

:   paclitaxel, oxaliplatin, leucovorin, and 5-FU

RECIST

:   Response Evaluation Criteria In Solid Tumors

TEAE

:   treatment-emergent adverse event
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